Navigation Links
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Date:7/24/2009

BOTHELL, WA and VANCOUVER, July 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has completed its registered direct offering, previously announced on July 20, 2009, of 475,000 shares of its common stock to institutional investors at a price of $20.00 per share, for gross proceeds to the Company of approximately $9.5 million. The $20 offering price represented a 3.5% discount to the closing price on July 17, 2009, the last trading day prior to announcement. After deducting the estimated offering expenses payable by the Company, the net proceeds are expected to be approximately $9.4 million.

The Company plans to use the net proceeds from the offering primarily for manufacturing readiness activities and general corporate purposes.

The shares of common stock offered by OncoGenex in this transaction were offered and sold pursuant to OncoGenex's existing shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on July 17, 2009. There was no placement agent or underwriter in this transaction.

Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission's web site at http://www.sec.gov, or from OncoGenex Pharmaceuticals, Inc., 1522 217th Pl. SE, Suite 100, Bothell, WA 98021-7617, Attention: Chief Financial Officer.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy the common stock of OncoGenex, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About OncoGenex
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
2. OncoGenex Pharmaceuticals Added to Russell Indexes
3. OncoGenex Pharmaceuticals Files Shelf Registration Statement
4. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
5. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
7. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
8. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
9. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... and Chinese Microcrystalline Cellulose Industry Report 2014" report ... Chinese Microcrystalline Cellulose Industry Report 2014 is a professional ... global microcrystalline cellulose industry with a focus on the ... overview of the industry including definitions, classifications, applications and ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 /PRNewswire/ ... today announced that it has entered into a ... which UHN,s Centre for Molecular Design and Preformulations ... project.  The goal of the project is to ... Company,s proprietary buccal insulin spray product, thereby reducing ...
(Date:9/22/2014)... Washington, D.C (PRWEB) September 22, 2014 ... the top privately held biotechnology companies of 2014. ... of companies before selecting this year’s winners. Those ... private biotechnology companies in the industry. , ... a new group of Fierce 15 companies," said Carroll. ...
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
Breaking Biology Technology:Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... PRINCETON, N.J., May 1 Ranbaxy Pharmaceuticals ... voluntary recall of all lots of Nitrofurantoin (Monohydrate/Macrocrystals) Capsules, ... U.S. Although certain lots of the product were ... laboratory specifications, Ranbaxy decided to recall all the lots, ...
... May 1 /PRNewswire-Asia/ -- Yongye Biotechnology International, Inc. (OTC ... distributor of plant and animal nutrient products located in ... of the independently owned Yongye branded retail stores in ... day sales.A Yongye branded retail store in Qianjiang City ...
... 1 Tigris Pharmaceuticals, Inc., a privately held drug ... a Phase I clinical trial of GGTI-2418. GGTI-2418 ... I) that induces apoptosis by downregulating several pivotal oncogenic ... by Dr. Peter O,Dwyer, Professor of Medicine at the ...
Cached Biology Technology:Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 2Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 3First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418 2First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418 3
(Date:9/19/2014)... will study multifunctional and specialized spinal cord nerve ... Science Foundation grant in the amount of $680,000 ... in the Department of Biology, OU College of ... between the multifunctional and specialized spinal cord nerve ... what connections they make. Berkowitz will collaborate ...
(Date:9/19/2014)... Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" or the ... updates the "Wocket in Your Pocket" celebrity ad campaign, featuring former ... classes, Vinny Pazienza (PAZ). , ... actor Ciaran Hinds and Sons of Anarchy ... have been cast in Bleed for This . ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... and biological aspects of cellular self-organization are well-studied; less ... how their behavior and communication are affected by ... the University of California San Diego, in a paper ... of the National Academy of Sciences, have begun ...
... Japanese researchers were awarded the 2008 SNM Wagner-Torizuka ... States through 2010 as part of the two-year ... Medical College, undertaking a fellowship at Johns Hopkins ... the University of Washington, Seattle; Ryo Nakazato, Toho ...
... has clearly illustrated, the top priority for the next ... Believing that expanding the nation,s commitment to basic ... the next President can take to ensure our long-term ... questions (attached) to the moderator of tomorrow,s presidential debate. ...
Cached Biology News:UC San Diego bioengineers fill holes in science of cellular self-organization 22008 SNM Wagner-Torizuka Fellowships announced 22008 SNM Wagner-Torizuka Fellowships announced 3The Science Coalition's '10 questions' for the presidential debate 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... has improved stability and convenience from the former ... has overcome this problem but also produced some ... the formulation of HRP conjugated antibody from lyophilized ... change, the stability of the conjugate has improved ...
... suitable for a wide range of molecular ... Pulsed Field Gel Electrophoresis (PFGE). Due to ... Multi ABgarose can effectively separate large DNA ... turn means reduced band diffusion, a problem ...
Biology Products: